Grifols/$GRFS

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX

About Grifols

Grifols SA one of is global specialty plasma therapeutics companies developing, manufacturing and distributing a broad range of biological medicines based on plasma derived proteins. Plasma derivatives are proteins found in human plasma, which once isolated and purified, have therapeutic value. These protein-based therapies extend and enhance the lives of individuals who suffer from chronic and acute, often life-threatening, conditions, including primary and secondary immunological deficiencies, Chronic Inflammatory Demyelinating Polyneuropathy, immune-mediated ITP. Products and services are used to diagnose and treat patients with hemophilia, immune deficiencies, infectious diseases and a range of other medical conditions. Majority of revenue is from USA.

Ticker

$GRFS
Sector
Primary listing

Employees

23,833

Grifols Metrics

BasicAdvanced
$8.4B
18.22
$0.53
0.97
$0.14
1.48%

What the Analysts think about Grifols

Analyst ratings (Buy, Hold, Sell) for Grifols stock.

Bulls say / Bears say

Grifols’ net profit almost tripled to €60 million in Q1 2025, boosted by a 7.4% year-on-year rise in net revenue to €1.79 billion, reinforcing confidence in its ability to achieve annual targets. (Reuters)
Shares jumped 13% after presenting its 2025 outlook, forecasting revenue between €7.5–7.6 billion and free cash flow of €350–400 million for the year, signaling strong investor support for its strategic plan. (Reuters)
On February 3, 2025, Grifols finalized the purchase of the remaining 14 plasma collection centers from ImmunoTek, securing full control of 28 centers in the U.S. and strengthening supply reliability and margin prospects. (SEC Form 20-F)
Despite recent refinancing efforts, Grifols’ net leverage remained high at 4.2x adjusted EBITDA as of H1 2025, which could limit its financial flexibility and heighten refinancing risks over the medium term. (Cinco Días)
Shares fell 8.7% over three trading days in early March after investors questioned the credibility of its long-term strategic plan, highlighting ongoing market concerns about management’s ability to deliver. (Cinco Días)
Legal disputes with short-seller Gotham City Research, including a U.S. court allowing Grifols’ defamation claim to proceed and a Spanish High Court investigation into Gotham, continue to present reputational risks and divert management attention from operations. (Reuters)
Data summarised monthly by Lightyear AI. Last updated on 29 Aug 2025.

Grifols Financial Performance

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

Grifols Earnings Performance

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $GRFS

Sign up or log in to buy
Capital at risk
Market closedADR

Upcoming events

No upcoming events
FAQs